natgillin/translations-raw huggingface dataset:
a sequence corresponding to a tissue specific promoter, which is the AFP promoter, 
sekvencu koja odgovara tkivno specifičnom promotoru, koji je AFP promotor,
a cDNA chain derived from an alphavirus, the sequence of which is partly complementary to an alphaviral RNA derived from the SFV virus, which comprises a sequence encoding for an exogenous gene of interest which is hIL-12, wherein said cDNA chain comprises: 
lanac cDNK porijeklom od alfavirusa, čija sekvenca je djelomično komplementarna alfavirusnoj RNK izvedenoj iz SFV virusa, koji sadrži najmanje sekvencu koja kodira egzogeni gen koji je hIL-12, gdje spomenuti cDNK lanac sadrži:
a 5' sequence necessary for replication of the alphavirus, 
5’ sekvencu neophodnu za replikaciju alfavirusa,
a cDNA chain derived from an alphavirus, the sequence of which is partly complementary to an alphaviral RNA derived from the SFV virus, which comprises a sequence encoding for an exogenous gene of interest selected from mIL-12 and LacZ, wherein said cDNA chain comprises: 
lanac cDNK porijeklom od alfavirusa, čija sekvenca je djelomično komplementarna alfavirusnoj RNK izvedenoj iz SFV virusa, koji sadrži najmanje sekvencu koja kodira egzogeni gen od interesa izabran od mIL-12 i LacZ, gdje spomenuti cDNK lanac sadrži:
A method for controlling undesired plants or inhibiting their growth, which comprises applying a herbicidally effective amount of the herbicidal composition as defined in Claim 1 to the undesired plants or to a place where they grow. 
Postupak za kontroliranje neželjenih biljaka ili sprječavanje njihovog rasta, naznačen time, da sadrži primjenu herbicidno učinkovite količine herbicidne smjese kako je defInirana u patentnom zahtjevu 1 na neželjene biljke ili na mjesta na kojima rastu.
A method for controlling undesired plants or inhibiting their growth, which comprises applying a herbicidally effective amount of from 1 to 200 g/ha of (A) as defined in Claim 1 and a herbicidally effective amount of from 100 to 5,000 g/ha of (B) as defined in Claim 1 to the undesired plants or to a place where they grow. 
Postupak za kontroliranje neželjenih biljaka ili sprječavanje njihovog rasta, naznačen time, da sadrži primjenu herbicidno učinkovite količine od 1 do 200 g/ha od (A) kako je definirano u patentnom zahtjevu 1 i herbicidno učinkovite količine od 100 do 500 g/ha od (B) kako je definirano u patentnom zahtjevu 1 na neželjene biljke ili na mjesta na kojima rastu.
The intrauterine contraceptive device of claim 1, wherein x+y is approximately 93 weight %. 
Intrauterina naprava za kontracepciju prema zahtjevu 1, naznačena time da x+y je približno 93 težinski %.
The intrauterine contraceptive device of claim 7, wherein the active metal alloy is placed onto the carrier body in a helical form. 
Intrauterina naprava za kontracepciju prema zahtjevu 7, naznačena time da aktivna metalna legura se postavlja na tijelo nosača u spiralnom obliku.
Food composition or dietary supplementation according to claim 1, wherein a dose of same has a weight of about 13.3g, said dose being configured in a manner which allows same to be consumed within a restaurant or a bar prior to the consumption of alcohol. 
Prehrambeni pripravak ili dijetetski dodatak prema zahtjevu 1, naznačen time da njegova doza ima težinu od oko 13.3g, navedena doza je oblikovana na način koji omogućuje istom da se konzumira u restoranu ili baru prije uzimanja alkohola.
Food composition or dietary supplementation according to any one of claims 1 to 10, wherein same is in the form of tablets. 
Prehrambeni pripravak ili dijetetski dodatak prema bilo kojem od zahtjeva 1 do 10, naznačen time da je isti u obliku tableta.
Food composition or dietary supplementation according to any one of claims I to 10, wherein said tablets or capsules are contained in a dosage receptacle. 
Prehrambeni pripravak ili dijetetski dodatak prema bilo kojem od zahtjeva 1 do 10, naznačen time da su navedene tablete ili kapsule sadržane u posudi za doziranje.
Food composition or dietary supplementation according to any one of claims I to 10, wherein same is in the form of cryopowder. 
Prehrambeni pripravak ili dijetetski dodatak prema bilo kojem od zahtjeva 1 do 10, naznačen time da je pripravak u obliku kriopraška.
Food composition or dietary supplementation according to any one of claims 1 to 10, wherein same is in the form of sirup. 
Prehrambeni pripravak ili dijetetski dodatak prema bilo kojem od zahtjeva 1 do 10, naznačen time da je pripravak u obliku sirupa.
Reducing ethanol metabolism by slowing down the process of ethanol oxidation into acetaldehyde, to prevent accumulation of acetaldehyde in the first place; 
smanjenje metabolizma etanola usporavanjem procesa oksidacije etanola u acetaldehid, kako bi se spriječilo nakupljanje acetaldehida na prvom mjestu;
Speeding up the reaction from acetaldehyde to acetic acid and further decomposition in the citrate cycle; 
ubrzavanje reakcije iz acetaldehida u octenu kiselinu i daljnje razgradnje u citratnom ciklusu;
Improving the levels of those anti-oxidants of the alcohol consumer which specially protect against toxic effects of acetaldehyde. 
poboljšanje razine onih anti-oksidanata kod potrošača alkohola koji posebice štite od toksičnog djelovanja acetaldehida.
Porous composite material comprising at least one interdispersed biopolymer with a mineral component comprising from 50 w/% to 95 w/% of a-tricalcium phosphate (a-TCP) and from 5 w/% to 50 w/% of octacalcium phosphate (OCP), to the total weight of the mineral component. 
Porozni kompozitni materijal, naznačen time što sadržava barem jedan interdispergirani biopolimer s mineralnom komponentom koja sadržava od 50 w/% do 95 w/% a-trikalcij fosfata (a-TCP) i od 5 w/% do 50 w/% oktakalcij fosfata (OCP), u odnosu na ukupnu težinu mineralne komponente.
Porous composite material according to claim 2, wherein the mineral component comprises from 70 w/% to 80 w/% of a-TCP and from 20 w/% to 30 w/% of OCP. 
Porozni kompozitni materijal prema zahtjevu 2, naznačen time što mineralna komponenta sadržava od 70w/% do 80 w/% a-TCP i od 20 w/% do 30 w/% OCP.
mixing at least one biopolymer with a mineral component essentially composed of a-tricalcium phosphate (a-TCP) in an aqueous medium so as to obtain a foam; leaving the so obtained foam for a sufficient time to obtain the biopolymer gelification; cooling the foam at a temperature lower than -20°C, 
miješanje barem jednog biopolimera s mineralnom komponentom koja je u biti sastavljena od a-trikalcij fosfata (a-TCP), u vodenom mediju tako da se dobije pjena; ostavljanje dobivene pjene kroz vrijeme dovoljno da se dobije gelirani biopolimer; hlađenje pjene pri temperaturi nižoj od -20°C, poželjno nižoj od -90°C; sušenje zamrzavanjem ohlađene pjene.
freeze-drying the cooled foam. Process according to claim 11, wherein at least one crosslinking agent is further added to the aqueous medium. 
Postupak prema zahtjevu 11, naznačen time što se dalje u vodeni medij dodaje barem jedno sredstvo za umrežavanje.
Process according to any of the claims from 11 to 13, wherein the freeze-drying phase is carried out at a temperature not over -20°C, preferably from -40 and -60°C, for a time not less than 18 hours, preferably between 24 hours and 3 days, under reduced pressure, less than 10 millibar, preferably from 0.1 and 1.0 millibar. 
Postupak prema bilo kojem od zahtjeva 11 do 13, naznačen time što se faza sušenja zamrzavanjem provodi pri temperaturi koja ne prelazi -20°C, poželjno od -40 i -60°C, kroz vrijeme koje nije kraće od 18 sati, poželjno između 24 sata i 3 dana, pod sniženim tlakom, manjim od 10 milibara, poželjno od 0.1 i 1.0 milibar.
Use of a porous composite material according to any of the claims from 1 to 10 for the manufacture of a material for bone and/or bone-cartilage regeneration. 
Uporaba poroznog kompozitnog materijala prema bilo kojem od zahtjeva 1 do 10, naznačena time što je za proizvodnju materijala za regeneraciju kosti i/ili koštane hrskavice.
Use of a porous composite material according to any of the claims from 1 to 10 for the manufacture of a tissue engineering device. 
Uporaba poroznog kompozitnog materijala prema bilo kojem od zahtjeva 1 do 10, naznačena time što je za proizvodnju uređaja za tkivni inženjering.
a plurality of modules (6a, 6b,6c) are arranged on a support surface (8) of the package (10) such that the modules are in an upright position with the front surfaces of the rolls or packages of panels of one row standing on the support surface; 
veći broj modula (6a, 6b,6c) postavljeni su na potpornu površinu (8) pakiranja (10) tako da se moduli nalaze u okomitom položaju pri čemu prednje površine valjaka ili paketa ploča jednog reda stoje na potpornoj površini;
compressed rolls (1a, 1b, 1c, 1d, 2a, 2b, 2c, 2d) of mineral wool which are individually packaged within a plastic film or compressed stacks of mineral wool panels (22a, 22b, 22c, 22d, 22e, 22f, 22g, 22h) which are packed in a plastic film (3) to form a package of panels, wherein 
stlačene valjke (Ia, Ib, Ic, Id, 2a, 2b, 2c, 2d) mineralne vune koji su pojedinačno pakirani u plastičnoj foliji ili stlačene stogove ploča od mineralne vune (22a, 22b, 22c, 22d, 22e, 22f, 22g, 22h) koji su pakirani u plastičnoj foliji (3) i čine paket ploča, pri čemu
fixing the modules (6) on the pallet (8), preferably by wrapping a further plastic film (9) around the package. 
učvršćivanje modula (6) na paletu (8), poželjno je omatanjem dodatne plastične folije (9) oko paketa.
1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine and pharmaceutically acceptable acid addition salts thereof (compound I) for use in a method for the treatment of pain. 
-[2-(2,4-dimetilfenilsulfanil)fenil]piperazin [image] i njegove farmaceutski prihvatljive kisele adicijske soli (spoj I), naznačen time, što se upotrebljavaju u metodi za liječenje bolova.
The compound according to claim 1, wherein compound I is the HBr acid addition salt. 
Spoj prema zahtjevu 1, naznačen time, što je spoj I kisela adicijska sol HBr.
The compound according to claim 3, wherein said HBr acid addition salts has an XRPD as depicted in Figure 3. 
Spoj prema zahtjevu 3, naznačen time, što spomenuta kisela adicijska sol HBr ima XRPD kakav je prikazan na Slici 3.
to 99 parts in dry weight of a fine particulate carbonate and/or of a fine particulate kaolin and/or of a fine particulate clay 
-99 dijelova u suhoj masi finih čestica nataloženog karbonata i/ili finih čestica mljevenog karbonata i/ili finih čestica kaolina i/ili finih čestica gline
5-20 parts in dry weight of binder and less than 4 parts in dry weight of additives. 
-20 dijelova u suhoj masi veziva i manje od 4 dijela u suhoj masi aditiva.
-80 parts in dry weight of a fine particulate carbonate with a particle size distribution such that 50% of the particles are smaller than 0.4 µm, 
-80 dijelova u suhoj masi finih čestica karbonata sa takvom raspodjelom veličine čestice da 50% čestica je manje od 0.4 µm,
-15 parts in dry weight of a fine particulate kaoline or clay with a particle size distribution such that 50% of the particles are smaller than 0.3 µm, 
-15 dijelova u suhoj masi finih čestica kaolina ili gline sa takvom raspodjelom veličine čestice da 50% čestica je manje od 0.3 µm,
-12 parts in dry weight of a latex binder less than 3 parts in dry weight of additives. 
-12 dijelova u suhoj masi lateks veziva manje od 3 dijela u suhoj masi aditiva.
Printing sheet according to any of the preceding claims, characterised in that it is calendered and/or in that it is a matt, glossy or a satin paper and/or in that in case of a glossy paper by a gloss on the surface of the image receptive coating of more than 75 % according to TAPPI 75deg or of more than 50 according to DIN 75deg, or characterised in case of a matt paper by a gloss on the surface of the image receptive coating of less than 25 % according to TAPPI 75deg, or characterised in case of a satin paper by a gloss on the surface of the image receptive coating in the intermediate range and/or in that an image receptive coating layer is provided on both sides of the substrate and/or in that the substrate is a woodfree paper substrate. 
Upotreba arka za tiskanje prema bilo kojem od prethodnih zahtjeva, naznačena time da je isti kalandriran. Upotreba arka za tiskanje prema bilo kojem od prethodnih zahtjeva, naznačena time da je isti mat, sjajni ili satenski papir. Upotreba arka za tiskanje prema bilo kojem od prethodnih zahtjeva, naznačena time da je u slučaju sjajnog papira sjaj na površini premaza koji prihvaća sliku od više od 75 % prema TAPPI 75deg ili od više od 50 prema DIN 75deg, ili time da je u slučaju mat papira sjaj na površini premaza koji prihvaća sliku od manje od 25 % prema TAPPI 75deg, ili time da je u slučaju satenskog papira sjaj na površini premaza koji prihvaća sliku u srednjem rasponu.
Printing sheet according to any of the preceding claims, characterised in that the image receptive coating layer has a second layer beneath said top layer comprising: a pigment part, wherein this pigment part is composed of 
Upotreba arka za tiskanje prema bilo kojem od prethodnih zahtjeva, naznačena time da sloj premaza koji prihvaća sliku ima drugi sloj ispod navedenog gornjeg sloja koji se sastoji od: pigmentnog dijela, pri čemu ovaj pigmentni dio se sastoji od:
80- 98 parts in dry weight of a mixture of or a single fine particulate carbonate, preferably with a particle size distribution such that 50% of the particles are smaller than 2 µm, 
dijelova u suhoj masi mješavine ili samostalnih finih čestica karbonata, poželjno sa takvom raspodjelom veličine čestice da 50% čestica je manje od 2 µm,
2-25 parts in dry weight of a fine particulate silica and a binder part, wherein this binder is composed of: less than 20 parts in dry weight of binder, preferably 8-15 parts in dry weight of latex or starch binder, 
-25 dijelova u suhoj masi finih čestica silikagela, i vezivnog dijela, pri čemu ovaj vezivni dio se sastoji od: manje od 20 dijelova u suhoj masi veziva, poželjno 8-15 dijelova u suhoj masi lateksa ili škrobnog veziva, manje od 4 dijela u suhoj masi aditiva.
Use of a printing sheet according to any of the claims 1-39 in a sheet fed offset printing process, wherein in that process reprinting and converting takes place within less than one hour, preferably within less than 0.5 hours, preferably it is reprinted within less than 30 minutes, even more preferably within less than 15 minutes and converted within less than one hour, preferably within less than 0.5 hours. 
Upotreba arka za tiskanje prema bilo kojem od zahtjeva 1-39 kod pojedinačnog uvođenja papira u postupku offset tiska, naznačena time da se postupak ponovnog-tiskanja i konverzije odvija unutar manje od jednog sata, poželjno unutar manje od 0.5 sati, poželjno se ponovno-tiska unutar manje od 30 minuta, čak još poželjnije unutar manje od 15 minuta i konvertira unutar manje od jednog sata, poželjno unutar manje od 0.5 sati.
A composition according to claim 1, which comprises as component (A) the compound 3-difluoromethyl-1-methyl-1 H-pyrazole-4-carboxylic acid (9-dichloromethylidene-benzonorbornene-5-yl)amide and as component (B) mandipropamid. 
Pripravak prema zahtjevu 1, naznačen time da je komponenta (A) 3-difluorometil-1-metil-1H-pirazol-4-karboksilna kiselina (9-diklorometiliden-benzonorbornen-5-il)amid i komponenta (B) je odabrana od azoksistrobina i pikoksistrobina.
A composition according to claim 1, which comprises as component (A) the compound 3-difluoromethyl-1-methyl-1 H-pyrazole-4-carboxylic acid (9-difluoromethylidene-benzonorbornene-5-yl)amide and as component (B) mandipropamid. 
Pripravak prema zahtjevu 1, naznačen time da je komponenta (A) 3-difluorometil-1-metil-1H-pirazol-4-karboksilna kiselina (9-difluorometiliden-benzonorbornen-5-il)amid i komponenta (B) je odabrana od azoksistrobina i pikoksistrobina.
A composition according to claim 1, which comprises as component (A) the compound 3-difluoromethyl-1-methyl-1H-pyrazole-4-carboxylic acid (9-dichloromethylidenebenzonorbornene-5-yl)amide and as component (B) fluopyram. 
Pripravak prema zahtjevu 1, naznačen time da je komponenta (A) 3-difluorometil-1-metil-1H-pirazol-4-karboksilna kiselina (9-diklorometiliden-benzonorbornen-5-il)amid i komponenta (B) je odabrana od azoksistrobina i pikoksistrobina.
A composition according to claim 1, which comprises as component (A) the compound 3-difluoromethyl-1-methyl-1H-pyrazole-4-carboxylic acid (9-difluoromethylidenebenzonorbornene-5-yl)amide and as component (B) fluopyram. 
Pripravak prema zahtjevu 1, naznačen time da je komponenta (A) 3-difluorometil-1-metil-1H-pirazol-4-karboksilna kiselina (9-difluorometiliden-benzonorbornen-5-il)amid i komponenta (B) je odabrana od azoksistrobina i pikoksistrobina.
Escitalopram free base in solid form characterised in that it is crystalline. 
Slobodna baza escitaloprama u čvrstom obliku, naznačena time, što sadrži kristalni escitalopram.
A pharmaceutical composition containing the escitalopram free base according to claim 1. 
Slobodna baza escitaloprama prema zahtjevu 1, naznačena time, što je kristalna.
A process according to claim 16 or 17 for the manufacture of a salt of escitalopram characterised in that an impurity of the formula (II) wherein Z is cyano, R1 is methyl and R2 is hydrogen is removed from or reduced in the escitalopram by the process. 
Postupak prema zahtjevu 16 ili 17 za proizvodnju soli escitaloprama, naznačen time, što se nečistoća formule (II) [image] gdje je Z cijano, R1 je metil i R2 je vodik, postupkom uklanja ili smanjuje u escitalopramu.
A process for preparing an influenza vaccine from influenza virus that has been grown in a culture of a mammalian cell line, comprising a step in which the seed virus and/or the vaccine and/or the culture is tested for the presence of an infectious agent that can grow in said cell line but that does not grow in embryonated hen eggs, wherein the infectious agent is selected from the group consisting of: Pneumovirinae; mammalian Reoviridae; Birnaviridae; Rubulaviruses of the Paramyxoviridae family; Coronaviridae; Rhinoviruses of the Picornaviridae family; Varicella Zoster virus; BK polyomavirus, JC polyomavirus; Echoviruses; Coxsackieviruses of the Enteroviruses of the Picornaviridae family; Rotavirus; Porcine picornaviruses; Parvovirus; Circovirus; and Chlamydia bacteria. 
Postupak za pripremanje cjepiva protiv gripe iz virusa gripe izraslog u kulturi MDCK stanične linije, koji sadrži stupanj u kojem se uzgojeni virus i/ili cjepivo i/ili kultura testira na prisutnost infekcijskog agensa koji može rasti u navedenoj staničnoj liniji, ali koji ne raste u embriju kokošjih jaja, naznačen time, da je navedeni infekcijski agens jedan ili više od sljedećih patogena: Reoviridae kod sisavaca; Pneumoviridae; Pneumovirusi od Pneumoviridae; Morbillivirusi iz familije Paramyxoviridae; Echovirusi od Enterovirusa iz familije Picornaviridae; ili Rotavirus.
Use of O-(3-piperidino-2-hydroxy-1-propyl)-nicotinic amidoxime or a pharmaceutically acceptable acid addition salt thereof for the preparation of a pharmaceutical composition for the prevention of abnormal body weight gain or reduction of overweight or obesity. 
Upotreba O-(3-piperidino-2-hidroksi-1-propil)-nikotinskog amidoksima ili njegove farmaceutski prihvatljive kisele adicijske soli naznačena time da je za pripremu farmaceutskog pripravka za prevenciju nenormalnog dobivanja na tjelesnoj težini ili za smanjenje prekomjerne težine ili pretilosti.
Use of a casing according to any one of claims 7 to 10 for the preparation of sausages, for the treatment of sausages, or for the preparation of a laminated casing product. 
Upotreba crijeva prema bilo kojem od zahtjeva od 7 do10 naznačena time da se koristi za pripremu kobasica, za preradu kobasica ili za pripremu proizvoda sa višeslojnim crijevom.
or R10 and R11 together with the two carbon atoms carying them represent a heteroaryl having 5 or 6 ring members or a heterocyclyl group having 5 or 6 ring members, which can be substituted by one of the following groups: halogen, hydroxy, nitro, cyano, trifluoromethyl, trifluoromethoxy, C1-6alkyl and C1-6alkoxy; 
ili R10 i R11 zajedno sa dva atoma ugljika koji ih nose predstavljaju heteroaril koji ima 5 ili 6 članova prstena ili heterociklilna skupina koja ima 5 ili 6 članova prstena, koji se mogu zamijeniti sa jednom od slijedećih skupina: halogen, hidroksi, nitro, cijano, trifluorometil, trifluorometoksi, C1-6alkil i C1-6alkoksi;
A compound of formula (I) according to claim 1, wherein R10 and R11 independently represent hydrogen, halogen, amino, hydroxyl, nitro, cyano, trifluoromethyl, trifluoromethoxy, C1-C6alkyl, C1-C6alkyloxy, cyclohexyl, phenyl, or a ring system from the group: thiophene, pyrrole, furane, pyrazole, tetrazole, oxazole, isoxazole, thiazole, pyridine, pyrimidine and morpholino. 
Spoj iz formule (I) temeljem zahtjeva 1, pri čemu R10 i R11 nezavisno predstavljaju vodik, halogen, amino, hidroksil, nitro, cijano, trifluorometil, trifluorometoksi, C1-C6alkil, C1-C6alkiloksi, cikloheksil, fenil, ili prstenasi sustav iz skupine: tiofena, pirola, furana, pirazola, tetrazola, oksazola, izoksazola, tiazola, piridina, pirimidina i morfolina.
A compound of formula (I) according to any one of the claims 1 to 6, wherein Y', Y2, Y3 and Y4 all represent a carbon atom. 
Spoj iz formule (I) temeljem bilo kojeg od zahtjeva 1 do 6, pri čemu Y’, Y2, Y3 i Y4 svi predstavljaju atom ugljika.
or R10 and R11 together with the two carbon atoms carying them represent a heteroaryl having 5 or 6 ring members or a heterocyclyl group having 5 or 6 ring members, which can be substituted by one of the following groups: halogen, hydroxy, nitro, cyano, trifluoromethyl, trifluoromethoxy, C1-6alkyl and C1-6alkoxy, in particular by methyl; 
ili R10 i R11 zajedno sa dva atoma ugljika koji ih nose predstavljaju heteroaril koji ima 5 ili 6 članova prstena ili heterociklilnu skupinu koja ima 5 ili 6 članova prstena, koja može biti zamijenjena s jednom od slijedećih skupina: halogen, hidroksi, nitro, cijano, trifluorometil, trifluorometoksi, C1-6alkil i C1-6alkoksi, naročito putem metila;
The solid oral extended release pharmaceutical dosage form of claim 1, wherein the extended release matrix formulation after having been stored at 25 °C and 60 % relative humidity (RH) for at least 1 month provides a dissolution rate, when measured in a USP Apparatus 1 (basket) at 100 rpm in 900 ml simulated gastric fluid without enzymes (SGF) at 37° C, characterized by the percent amount of active agent released at 1, 4 and 12 hours of dissolution that deviates no more than about 15 % points from the corresponding in-vitro dissolution rate of a reference formulation prior to storage. 
Farmaceutski oblik doziranja s produljenim otpuštanjem u krutom obliku prema zahtjevu 1 ili 2, pri čemu formulacija matrice s produljenim otpuštanjem nakon što je skladištena pri 25 °C i 60 % relativne vlažnosti zraka barem 1 mjesec daje stupanj otapanja, kad je mjerena u USP uređaju (koš) pri 100 rpm u 900 ml simulirane želučane tekućine bez prisustva enzima (SGF) pri 37 °C, naznačen time da je postotna količina aktivnog agensa oslobođena pri 1, 4 ili 12 sati otapanja koja odstupa ne više od oko 15 % točaka od odgovarajuće in-vitro stupnja otapanja referentne formulacije prije skladištenja.